Poplar Forest Capital LLC Takes Position in Humana Inc. (NYSE:HUM)

Poplar Forest Capital LLC acquired a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,938 shares of the insurance provider's stock, valued at approximately $5,276,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Dodge & Cox increased its stake in shares of Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock valued at $2,587,345,000 after purchasing an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Humana by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after purchasing an additional 1,751,857 shares during the last quarter. Norges Bank bought a new position in Humana in the fourth quarter worth approximately $416,202,000. GAMMA Investing LLC raised its position in Humana by 40,881.1% in the first quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider's stock worth $2,066,790,000 after acquiring an additional 779,193 shares during the period. Finally, Southpoint Capital Advisors LP bought a new position in Humana in the fourth quarter worth approximately $190,282,000. 92.38% of the stock is owned by institutional investors.

Humana Stock Performance

HUM opened at $231.89 on Wednesday. The firm has a market capitalization of $27.99 billion, a PE ratio of 16.40, a PEG ratio of 1.53 and a beta of 0.44. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $406.09. The firm's 50-day moving average price is $234.87 and its 200 day moving average price is $257.29. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.71.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. Humana's revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the business posted $7.23 EPS. As a group, sell-side analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on HUM. Truist Financial reduced their price target on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Robert W. Baird boosted their target price on shares of Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, April 15th. Barclays set a $268.00 target price on shares of Humana and gave the stock an "equal weight" rating in a report on Thursday, June 12th. Wells Fargo & Company set a $348.00 target price on shares of Humana in a report on Friday. Finally, Bank of America reduced their target price on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a report on Tuesday, June 17th. Sixteen research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Humana currently has an average rating of "Hold" and a consensus target price of $282.57.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.